TY - JOUR
T1 - The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration
AU - Perumalswami, Ponni V.
AU - Kilpatrick, Sidonie
AU - Frost, Madeline C.
AU - Adams, Megan A.
AU - Kim, Hyungjin Myra
AU - Zhang, Lan
AU - Lin, Lewei
N1 - Funding Information:
The opinions expressed in this work are the authors’ and do not necessarily reflect those of the institutions, funders, the Department of Veterans Affairs, or the United States Government. This work was supported by funding from the VA Office of Connected Care (OCC 21‐11). L.A.L. is also supported by a US Department of Veterans Affairs Health Services Research and Development Career Development Award (CDA 18‐008) and CDC R49 CE003085.
Funding Information:
The opinions expressed in this work are the authors’ and do not necessarily reflect those of the institutions, funders, the Department of Veterans Affairs, or the United States Government. This work was supported by funding from the VA Office of Connected Care (OCC 21-11). L.A.L. is also supported by a US Department of Veterans Affairs Health Services Research and Development Career Development Award (CDA 18-008) and CDC R49 CE003085.
Publisher Copyright:
© 2023 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
PY - 2023
Y1 - 2023
N2 - Background and Aims: The COVID-19 pandemic disrupted health-care provision in the United States and prompted increases in telehealth-delivery of care. This study measured alcohol use disorder (AUD) treatment trends across visit modalities before and during COVID-19. Design, Setting, Participants and Measurements: We conducted a national, retrospective cohort study with interrupted time-series models to estimate the impact of COVID-19 on AUD treatment in the Veterans Health Administration (VHA) in the United States during pre-COVID-19 (March 2019 to February 2020) and COVID-19 (March 2020 to February 2021) periods. We analyzed monthly trends in telephone, video and in-person visits for AUD treatment and compared patient and treatment characteristics of patients receiving AUD treatment between the pre-COVID-19 and COVID-19 periods. AUD was defined using International Classification of Diseases, 10th revision (ICD-10) codes for alcohol abuse (F10.1) and alcohol dependence (F10.2), which have previously been used to study AUD in VHA. Findings: The predicted percentage of VHA patients with an AUD diagnosis receiving any AUD treatment at the beginning of the pre-COVID period was 13.8% (n = 49 494). The predicted percentage decreased by 4.3% (P = 0.001) immediately at the start of the COVID-19 period due to a decline in AUD psychotherapy. Despite an increase of 0.3% per month (P = 0.026) following the start of COVID-19, the predicted percentage of VHA patients with an AUD diagnosis receiving any AUD treatment at the end of the study period remained below the pre-COVID-19 period. In February 2021, AUD psychotherapy visits were primarily delivered by video (50%, 58 748), followed by in-person (36.6%, 43 251) and telephone (13.8%, 16 299), while AUD pharmacotherapy visits were delivered by telephone (38.9%, 3623) followed by in-person (34.3%, 3193) and video (26.8%, 2498) modalities. Characteristics of VHA patients receiving AUD treatment were largely similar between pre-COVID-19 and COVID-19 periods. Conclusions: Despite increased telehealth use, the percentage of United States Veterans Health Administration patients with an alcohol use disorder (AUD) diagnosis receiving AUD treatment declined during COVID-19 (March 2020 to February 2021) mainly due to a decrease in psychotherapy.
AB - Background and Aims: The COVID-19 pandemic disrupted health-care provision in the United States and prompted increases in telehealth-delivery of care. This study measured alcohol use disorder (AUD) treatment trends across visit modalities before and during COVID-19. Design, Setting, Participants and Measurements: We conducted a national, retrospective cohort study with interrupted time-series models to estimate the impact of COVID-19 on AUD treatment in the Veterans Health Administration (VHA) in the United States during pre-COVID-19 (March 2019 to February 2020) and COVID-19 (March 2020 to February 2021) periods. We analyzed monthly trends in telephone, video and in-person visits for AUD treatment and compared patient and treatment characteristics of patients receiving AUD treatment between the pre-COVID-19 and COVID-19 periods. AUD was defined using International Classification of Diseases, 10th revision (ICD-10) codes for alcohol abuse (F10.1) and alcohol dependence (F10.2), which have previously been used to study AUD in VHA. Findings: The predicted percentage of VHA patients with an AUD diagnosis receiving any AUD treatment at the beginning of the pre-COVID period was 13.8% (n = 49 494). The predicted percentage decreased by 4.3% (P = 0.001) immediately at the start of the COVID-19 period due to a decline in AUD psychotherapy. Despite an increase of 0.3% per month (P = 0.026) following the start of COVID-19, the predicted percentage of VHA patients with an AUD diagnosis receiving any AUD treatment at the end of the study period remained below the pre-COVID-19 period. In February 2021, AUD psychotherapy visits were primarily delivered by video (50%, 58 748), followed by in-person (36.6%, 43 251) and telephone (13.8%, 16 299), while AUD pharmacotherapy visits were delivered by telephone (38.9%, 3623) followed by in-person (34.3%, 3193) and video (26.8%, 2498) modalities. Characteristics of VHA patients receiving AUD treatment were largely similar between pre-COVID-19 and COVID-19 periods. Conclusions: Despite increased telehealth use, the percentage of United States Veterans Health Administration patients with an alcohol use disorder (AUD) diagnosis receiving AUD treatment declined during COVID-19 (March 2020 to February 2021) mainly due to a decrease in psychotherapy.
KW - Alcohol use disorder
KW - COVID-19
KW - substance use disorders
KW - telehealth
KW - telemedicine
KW - veterans
UR - http://www.scopus.com/inward/record.url?scp=85149336430&partnerID=8YFLogxK
U2 - 10.1111/add.16156
DO - 10.1111/add.16156
M3 - Article
AN - SCOPUS:85149336430
SN - 0965-2140
VL - 118
SP - 1062
EP - 1071
JO - Addiction
JF - Addiction
IS - 6
ER -